midodreine in cirrhotic patients with refractory ascites

The effects of Midodrine on patients with liver cirrhosis and refractory ascites

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202306748777678

Enrollment

Registered

2023-06-27

Start date

2021-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System

Interventions

midodrine 2.5 mg and SMT

Standard medical treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Cirrhotic patients more than 18 years • Cirrhosis secondary to any etiology. • Cirrhosis was diagnosed by US evaluation. 2-Patients with refractory ascites. The willing to sign informed consent and ready for regular follow-up during the study.

Exclusion criteria

Exclusion criteria: • Patients with acute or chronic renal disease. • Patients with cardiac disease: 1-Coronary heart disease. 2-Abnormal blood pressure. 3-Congestive heart failure. • Hepatocellular carcinoma. • Portal vein thrombosis.

Design outcomes

Primary

Measure	Time frame
The primary outcome of the study is to assess the effect of midodrine on body weight, abdominal girth and urine volume.	—

Secondary

Measure	Time frame
to assess the safety of midodrine as a treatment for refractory ascites.	—

Countries

Egypt

Contacts

Public Contactmohamed gamal

essamaboelnasr1993@gmail.com011110317093

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026